Ute Hoch Selected Research

vosaroxin

2/2011	Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
4/2010	Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
6/2009	Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
3/2009	Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ute Hoch Research Topics

Disease

20	Neoplasms (Cancer) 10/2022 - 09/2008
10	Breast Neoplasms (Breast Cancer) 01/2022 - 06/2009
6	Melanoma (Melanoma, Malignant) 10/2021 - 06/2009
5	Brain Neoplasms (Brain Tumor) 01/2022 - 10/2015
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 01/2020
3	Neutropenia 12/2017 - 11/2013
2	Disease Progression 01/2022 - 12/2017
2	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2015
2	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 12/2017
2	Diarrhea 12/2017 - 01/2013
2	Nausea 12/2017 - 11/2013
2	Vomiting 12/2017 - 11/2013
2	Septic Shock (Toxic Shock Syndrome) 11/2015 - 11/2013
2	Acute Kidney Injury (Acute Renal Failure) 11/2015 - 11/2013
2	Multiple Myeloma 06/2010 - 09/2009
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2010 - 09/2009
2	Ovarian Neoplasms (Ovarian Cancer) 04/2010 - 03/2009
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2010 - 03/2009
1	Carcinoma (Carcinomatosis) 10/2022
1	Urologic Neoplasms (Urological Cancer) 10/2022
1	Syncope (Fainting) 01/2022
1	Miosis 01/2020
1	Sleepiness 01/2020
1	Opioid-Related Disorders (Opiate Addiction) 01/2020
1	Dizziness (Lightheadedness) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Fibrosarcoma 01/2020
1	Circulating Neoplastic Cells 01/2018
1	Abdominal Pain (Pain, Abdominal) 12/2017
1	Kidney Neoplasms (Kidney Cancer) 02/2016
1	Pneumonia (Pneumonitis) 11/2015
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2015
1	Sepsis (Septicemia) 11/2015
1	Dehydration (Water Stress) 11/2013
1	Fatigue 11/2013
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2013
1	Dry Eye Syndromes (Dry Eye Syndrome) 03/2012
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2011
1	Peritonitis 09/2010
1	Colonic Neoplasms (Colon Cancer) 03/2010

Drug/Important Bio-Agent (IBA)

13	etirinotecan pegolIBA 01/2022 - 01/2013
9	bempegaldesleukinIBA 10/2022 - 02/2016
6	Irinotecan (Camptosar)FDA LinkGeneric 01/2018 - 01/2013
5	Interleukin-2 (IL2)IBA 10/2021 - 02/2016
5	Pharmaceutical PreparationsIBA 01/2020 - 06/2009
4	NivolumabIBA 10/2022 - 01/2020
4	taxaneIBA 09/2017 - 11/2013
4	AnthracyclinesIBA 09/2017 - 02/2011
4	vosaroxinIBA 02/2011 - 03/2009
3	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2018
3	Interleukin-2 Receptors (IL 2 Receptor)IBA 01/2019 - 02/2016
3	Capecitabine (Xeloda)FDA Link 09/2017 - 11/2015
3	Aurora KinasesIBA 03/2010 - 09/2008
2	CytokinesIBA 01/2019 - 02/2016
2	Topoisomerase I InhibitorsIBA 01/2018 - 12/2014
2	PolymersIBA 09/2017 - 12/2014
2	N- (5- (((5- (1,1- dimethylethyl)- 2- oxazolyl)methyl)thio)- 2- thiazolyl)- 4- piperidinecarboxamideIBA 06/2010 - 09/2009
2	SNS 314IBA 03/2010 - 09/2009
2	Caspase 3 (Caspase-3)IBA 03/2010 - 06/2009
1	Cisplatin (Platino)FDA LinkGeneric 10/2022
1	ProdrugsIBA 10/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Lipase (Acid Lipase)FDA Link 01/2022
1	InterferonsIBA 01/2020
1	Opioid Analgesics (Opioids)IBA 01/2020
1	NKTR-181IBA 01/2020
1	Oxycodone (Oxycontin)FDA LinkGeneric 01/2020
1	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2020
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2018
1	Gemcitabine FDA Link 09/2017
1	Docetaxel (Taxotere)FDA Link 09/2017
1	130-nm albumin-bound paclitaxelIBA 09/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 09/2017
1	eribulin FDA Link 09/2017
1	ixabepilone (BMS 247550)FDA Link 09/2017
1	Vinorelbine (Navelbine)FDA LinkGeneric 09/2017
1	CamptothecinIBA 01/2017
1	aldesleukin (Proleukin)FDA Link 02/2016
1	Cholinergic Agents (Cholinergics)IBA 01/2013
1	1,2,3,4-tetrahydroisoquinolineIBA 03/2012
1	lifitegrastIBA 03/2012
1	Ophthalmic Solutions (Eye Drops)IBA 03/2012
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 03/2012
1	Etoposide (VP 16)FDA LinkGeneric 02/2011
1	Topoisomerase II InhibitorsIBA 02/2011
1	EstersIBA 09/2010
1	QuinolonesIBA 04/2010
1	Histones (Histone)IBA 03/2010
1	Urea (Carbamide)FDA LinkGeneric 09/2009
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2009
1	2-aminobenzimidazoleIBA 09/2009
1	CaspasesIBA 06/2009

Therapy/Procedure

7	Therapeutics 10/2022 - 02/2011
5	Drug Therapy (Chemotherapy) 10/2022 - 02/2011
4	Immunotherapy 01/2020 - 02/2016
1	Radiotherapy 01/2020
1	Aftercare (After-Treatment) 01/2018
1	Intravenous Infusions 11/2015
1	Intravenous Administration 09/2010
1	Oral Administration 09/2010